Enterprise Value
574.3M
Cash
249M
Avg Qtr Burn
-21.71M
Short % of Float
27.83%
Insider Ownership
3.72%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OP-1250 (palazestrant) (CER antagonist) Details Metastatic breast cancer, Cancer | Phase 3 Data readout | |
OP-1250 (palazestrant) +ribociclib or alpelisib Details Breast cancer, Metastatic breast cancer, Cancer | Phase 2 Data readout | |
OP-1250 (palazestrant) +palbociclib Details Metastatic breast cancer, Breast cancer, Cancer | Phase 1/2 Update | |
OP-1250 (palazestrant) + everolimus Details Metastatic breast cancer, Breast cancer, Cancer | Phase 1/2 Initiation | |
OP-3136 Details Cancer, ER+/HER2- breast cancer | IND Submission |